In the absence of physical meetings, the Inborn Errors of Metabolism team understands that there is still huge value to the inherited metabolic disease community in providing an alternative platform for knowledge sharing and scientific corroboration. As such, the Inborn Errors of Metabolism Drug Development summit has gone digital!

Join our community of inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. This summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases.

With scarce treatment options leaving inborn errors of metabolism a devastating, unfilled, and unmet medical need, the opportunity for biopharma to do better and aggressively tap into a lucrative and life-changing market of gene modalities is growing.

For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety, and commercial viability.

Incorporating insights from industry-leading speakers, this conference will delve into the key patient access, regulatory, clinical, and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfill their full commercial potential.

This is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.